{"id":"W3037506839","doi":"10.1016/j.jtho.2020.06.015","title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Bayer; Servier; Astellas Pharma; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; F. Hoffmann-La Roche; AbbVie; Merck; Spectrum Pharmaceuticals; Celgene; Novartis; Sanofi; PharmaMar; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Roche; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Oncology; Placebo; Protocol (science); Internal medicine; Chemotherapy; Randomized controlled trial; Immunotherapy; Cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059512,0.0002490053,0.004232136,0.0007899617,0.00002398509,0.000008355512,0.0002149696,0.000146458,0.0004198424],"category_scores_gemma":[0.0005416651,0.0001544921,0.001115503,0.001105249,0.0002745107,0.00009090792,0.00001921175,0.0003953413,6.807962e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000335784,"about_ca_system_score_gemma":0.001129282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003148515,"about_ca_topic_score_gemma":0.00002738635,"domain_scores_codex":[0.9956783,0.0009107441,0.002274722,0.0002116245,0.0006814919,0.0002430917],"domain_scores_gemma":[0.9952867,0.0009031449,0.002974867,0.0002133186,0.0004798811,0.0001421018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9722434,0.002019424,0.0005346679,0.0001755645,0.006921904,0.00007406766,0.001195859,0.0003016553,0.0003707386,0.000004834872,0.0001209444,0.01603699],"study_design_scores_gemma":[0.968631,0.02010079,0.003651335,0.0001268223,0.005088867,0.00002084446,0.0001773716,0.001022183,0.0005210948,0.00001427525,0.0005165386,0.000128837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9568908,0.0001024285,0.0006983184,0.001942402,0.0001187359,0.03977627,0.000009408229,0.000006474519,0.0004551775],"genre_scores_gemma":[0.9950327,0.00002570189,0.001633664,0.0005095219,0.0001271221,0.002580229,0.000005917028,0.00002434497,0.00006079732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03814191,"threshold_uncertainty_score":0.6300007,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0330906876140015,"score_gpt":0.3841235725741152,"score_spread":0.3510328849601138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}